ULTRAGENYX PHARMACEUTICAL INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Pharmaceuticals

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$390,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.